Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews

Shunlong Ou(University of Electronic Science and Technology of China), Qian Jiang(Peking University), Suya Du(University of Electronic Science and Technology of China), Hua Wei(People's Hospital of Shiyan), Xiaoli Qin(Third People's Hospital of Chengdu), Song Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Luo(Second People’s Hospital of Yibin)
Frontiers in Immunology
July 13, 2022
Cited by 22


Related Papers